Prognosis for cows with severe clinical coliform mastitis

Golodetz, CL; White, MB

doi:10.1136/vr.112.17.402

Cited by 14 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 95 per cent confidence intervals indicate that the actual survival rate for 95 per cent of the population would be between 39 and 67 per cent. Previous work has examined the outcome of coliform mastitis, without separating systemic and toxic types, and found a survival rate of 93.2 per cent (Gollodetz and White 1983), substantially higher than in the current study. The difference is likely to be due to the better chance of surviving a non.toxic disease.…”

Section: Discussioncontrasting

confidence: 74%

Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis

Green¹,

Green

Cripps

1997

Veterinary Record

View full text Add to dashboard Cite

During a three-year study, 54 cows with toxic mastitis were allocated randomly to one of three treatment groups (A, B and C). Each cow was re-examined within 24 hours of the initial examination, and, during this time, group A received fluid therapy (45 liters of intravenous isotonic electrolyte solution) and flunixin meglumine (2000 mg), group B received fluid therapy only, and group C received flunixin meglumine only. In addition all the cases were treated with parenteral and intramammary tetracyclines, oxytocin and calcium boroglucoanate. There was no significant difference in the rate of survival between the treatment groups and 29 of the cows (53.7 per cent, 95 per cent confidence interval of 39 to 67 per cent) survived.

show abstract

Section: Discussioncontrasting

confidence: 74%

Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis

Green¹,

Green

Cripps

1997

Veterinary Record

View full text Add to dashboard Cite

show abstract

“…There are invisible inflammatory changes in subclinical cows’ udders, except for a drop in milk production [ 23 ]. Considering S. aureus infection is the main reason to cause subclinical mastitis [ 24 ], the object of the present study was subclinical mastitis Holstein cows induced by S. aureus based on a series of bacteria identification.…”

Section: Resultsmentioning

confidence: 99%

Whole-genome regulation analysis of histone H3 lysin 27 trimethylation in subclinical mastitis cows infected by Staphylococcus aureus

Song

Zhang

et al. 2016

BMC Genomics

View full text Add to dashboard Cite

BackgroundS. aureus is one of the major etiological agents causing bovine subclinical mastitis. The regulatory effects of H3K27me3 on gene expression in subclinical S. aureus mastitis cows are unknown. This study aimed to profile genome-wide transcriptional changes regulated by H3K27me3 in bovine lymphocytes applied in subclinical S. aureus mastitis cows and healthy controls.ResultsA total of 61 differentially expressed genes (DEGs) were detected in subclinical S. aureus mastitis cows compared to the healthy controls, of which 25 DEGs are up-regulated and the rest are down-regulated genes in subclinical S.aureus mastitis cows. The up-regulated genes are mainly involved in the Jak-STAT signaling pathway, cytokine-cytokine receptor interaction, and T cell receptor-signaling pathway, while the down-regulated genes are related to metabolism pathways. Combination analysis of histone methylation and gene expression revealed that H3K27 trimethylation levels in silent genes were higher in subclinical S. aureus mastitis cattle than in healthy cows. The key regions of H3K27me3 target genes related to subclinical S. aureus mastitis were the upstream 2 kb regions of the DEGs relative to transcription start site (TSS).ConclusionsThe current study provides a novel insight into the interaction between S. aureus and lymphocytes in lactating cows by histone H3 methylation regulation. The differentially expressed genes in bovine lymphocytes regulated by H3K27me3 on upstream 2 kb regions (IL10, PTX3 and etc.) may relate to S. aureus mastitis susceptibility and could be considered as key candidate genes for anti- S. aureus mastitis study and breeding.Electronic supplementary materialThe online version of this article (doi:10.1186/s12864-016-2947-0) contains supplementary material, which is available to authorized users.

show abstract

“…In contrast, in a Finnish study using an experimental E. coli mastitis model, bacteremia was not detected (Pyörälä et al ., ). After elimination of the infection, signs of inflammation, such as increased milk SCC, can persist in the infected quarter for several weeks, and the quarter may become blind (Golodetz & White, ; Erskine et al ., ; Pyörälä & Pyörälä, ).…”

Section: Characteristics Of Escherichia Coli Mastitismentioning

confidence: 99%

Treatment for bovineEscherichia colimastitis – an evidence‐based approach

Suojala

Kaartinen

Pyörälä

2013

Vet Pharm & Therapeutics

137

110

View full text Add to dashboard Cite

Bovine mastitis caused by Escherichia coli can range from being a subclinical infection of the mammary gland to a severe systemic disease. Cow-dependent factors such as lactation stage and age affect the severity of coliform mastitis. Evidence for the efficacy of antimicrobial treatment for E. coli mastitis is very limited. Antimicrobial resistance is generally not a limiting factor for treatment, but it should be monitored to detect changes in resistance profiles. The only antimicrobials for which there is some scientific evidence of beneficial effects in the treatment for E. coli mastitis are fluoroquinolones and cephalosporins. Both are critically important drugs, the use of which in animals destined for food should be limited to specific indications and should be based on bacteriological diagnosis. The suggested routine protocol in dairy herds could target the primary antimicrobial treatment for mastitis, specifically infections caused by gram-positive bacteria. In E. coli mastitis with mild to moderate clinical signs, a non-antimicrobial approach (anti-inflammatory treatment, frequent milking and fluid therapy) should be the first option. In cases of severe E. coli mastitis, parenteral administration of fluoroquinolones, or third- or fourth-generation cephalosporins, is recommended due to the risk of unlimited growth of bacteria in the mammary gland and ensuing bacteremia. Evidence for the efficacy of intramammary-administered antimicrobial treatment for E. coli mastitis is so limited that it cannot be recommended. Nonsteroidal anti-inflammatory drugs have documented the efficacy in the treatment for E. coli mastitis and are recommended for supportive treatment for clinical mastitis.

show abstract

Prognosis for cows with severe clinical coliform mastitis

Cited by 14 publications

References 0 publications

Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis

Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis

Whole-genome regulation analysis of histone H3 lysin 27 trimethylation in subclinical mastitis cows infected by Staphylococcus aureus

Treatment for bovineEscherichia colimastitis – an evidence‐based approach

Contact Info

Product

Resources

About